Cancer Breakthroughs, Blockchain Bets, and Biotech Boldness
DENVER, Colo., Sep 05, 2025 (247marketnews.com)- LIXTE (NASDAQ:LIXT) headlines the morning buzz as it continues to position its lead compound, LB-100, as a transformational player in oncology. LB-100 is the world’s only clinical-stage inhibitor of protein phosphatase 2A (PP2A), a regulatory enzyme exploited by cancer cells to survive traditional therapies.
Described as a “cancer power-up”, LB-100 doesn’t just kill tumor cells, it forces them into “lethal activation,” enhances visibility to the immune system, and supercharges chemo, immunotherapy, and radiation. Currently, the compound is being evaluated in trials for:
- Ovarian clear-cell carcinoma [in collaboration with GlaxoSmithKline plc (NYSE:GSK)],
- MSS colorectal cancer [with Roche Holding AG (OTCQX:RHHBY)], though enrollment is temporarily paused,
- And previously in soft-tissue sarcoma, where Phase 1 showed favorable safety, though the focus is shifting to higher-potential indications.
Roche Holding AG (SIX:RO)(OTCQX:RHHBY) continues its diagnostic dominance with CE IVDR approval for two key expansions of its VENTANA HER2 (4B5) assay. The update marks a leap forward in two high-need indications:
- HER2-ultralow metastatic breast cancer, where ENHERTU [by Daiichi Sankyo and AstraZeneca (NASDAQ:AZN)] offers new hope,
- And HER2-positive biliary tract cancer, enabling access to ZIIHERA (Jazz Pharmaceuticals’ zanidatamab-hrii).
“This is about creating new options for patients facing some of the toughest cancers,” said Roche Diagnostics’ Jill German, emphasizing Roche’s goal of precision treatment through cutting-edge diagnostics.
Notably, the DESTINY-Breast06 trial underpins the test’s value, showing significantly improved progression-free survival with ENHERTU in HER2-low and ultralow patients. Roche’s diagnostics arm continues to lead the charge toward individualized therapy access across Europe.
iSpecimen (NASDAQ:ISPC) is breaking out of biotech’s traditional mold and into blockchain. The biospecimen marketplace is building a $200 million digital asset treasury centered around Solana (SOL), aiming to diversify its balance sheet and support long-term initiatives.
CEO Robert Lim stated that while the company is interested in “Locked SOL,” it’s also exploring a mix of liquid staking, tokenized assets, and selective spot trading. ISPC is in discussions with several crypto firms and plans to purchase SOL (locked and unlocked) via OTC transactions, pending legal and compliance vetting.
Meanwhile, iSpecimen closed a $1.75 million private placement to fund marketing and general operations. The company issued 1.56 million shares at $1.122 each, signaling confidence in its hybrid biotech-blockchain growth thesis.
Palisade Bio (NASDAQ:PALI) gained regulatory momentum after receiving a No Objection Letter from Health Canada for its Phase 1b trial of PALI-2108, the first dual anti-inflammatory and anti-fibrotic therapy for fibrostenotic Crohn’s disease (FSCD), a condition affecting up to half of Crohn’s patients and currently without approved antifibrotic treatment.
Phase 1b will assess safety, pharmacokinetics, and pharmacodynamics across 6–12 patients. Top-line data are expected in Q1 2026, with Phase 2 IND submissions to the FDA planned shortly thereafter. CMO Dr. Mitchell Jones highlighted PALI-2108’s potential to go “beyond symptom management to alter the course of FSCD.”
Please go to https://247marketnews.com/lixte-biotechnology/ for further LIXT information and 247marketnews.com LIXT disclosure information.
About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.
24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.
CONTACT:
24/7 Market News
Editor@247marketnews.com